Novartis’ Phase III trial investigating Scemblix (asciminib) as a first-line therapy in Philadelphia chromosome-positive chronic myeloid leukaemia (CML) has met its primary endpoints.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,